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Cost-effectiveness analysis (CEA) presenting a cost/QALY ratio is
considered the gold standard for economic evaluations in health
care. Despite the proliferation of CEA research, there has been no
detailed study focusing on the bibliometric properties of this
literature. To describe and analyze trends in publications and
co-authorship in the CEA literature from 1976–2005. We used
the Tufts-New England Medical Center registry of original CEAs
published through 2005 http://www.tufts-nemc.org/cearegistry/).
For each article we recorded the year of publication, journal’s
name, the number of contributing authors and their names.
Authors were assigned a credit based on their perceived contri-
bution to the study (1 credit point for the ﬁrst and last authors,
1/2 point for the second author, and 1/n credit points for all other
authors). We calculated the Author’s Contribution Index (ACI),
by dividing the total credit points by the number of studies
published by the same author. Approximately 1150 studies have
been published in 360 journals over the past 30 years, with an
increase in the number published annually from 18(26) in
1976–2000 to 138(46) in 2001–2005, p < 0.0001. The mean
number of contributing authors was 4.6(2.4) and increased
from 4.3(2.3) to 4.8(2.5), p < 0.0001 over that same time
interval. Medical journals were characterized by a higher number
of co-authors, as compared with the economic and health policy
literature: 4.7(2.4) vs. 4.2(2.1), p = 0.004. The lowest
number of co-authors (3.6) was in Value in Health and Medical
Decision Making, and the highest in Circulation (7.7). The most
proliﬁc authors were afﬁliated with Harvard and Tufts Universi-
ties. CONCLUSIONS: The CEA literature continues to prolifer-
ate. Co-authorship trends seem to follow the rapid increase in the
mean number of authors found in the health economics and
medical literature. Further research is needed to examine jour-
nals’ and authors’ concentration trends, and dissemination of
CEA results.
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The incremental cost-effectiveness ratio (ICER) with number of
dollars per quality-adjusted life year (QALY) has been exten-
sively used in cost-effectiveness analysis (CEA) for improving
efﬁciency in health care, but there is a lack of simple CEA
indicators to take the equity issue in health into consideration. In
this paper, by adjusting the ordinary ICERs with the quality-
adjusted life expectancy (QALE) of the age- and gender-matched
general population, we developed the CEA indicators based on
and/or weighted by relative health gap to improve the distribu-
tive justice. If we collect the quality of life and survival data to
estimate the QALY gained by a certain intervention for a speciﬁc
disease, then the CEA indicators based on and/or weighted by
relative health gain can also be developed to reduce the unin-
tended inequity. The proposed six new CEA indicators with
equity implications were empirically calculated for comparisons
among the diseases of end stage renal disease, acquired immune
deﬁciency syndrome, liver cancer, and breast cancer to demon-
strate their applicability.
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Deﬁned as the psychophysiologic response associated with pla-
cebos, the placebo effect is of considerable interest to researchers
and clinicians. To ensure that study participants remain blinded
to treatment, a placebo must resemble the investigational
product in all aspects except for physiological activity: it should
have the same shape, colour, delivery mode, smell and taste. To
produce a placebo with all of these qualities, the development
cost and, thus, the daily cost of providing them to patients in a
clinical trial, can be signiﬁcant. Cost-effectiveness analyses
(CEAs) typically use efﬁcacy and safety data from RCTs. In fact,
phase 3 RCT data are often considered the most robust data
source in CEAs. By subtracting the clinical effect in the placebo
arm from the clinical effect in the active arm, CEAs remove the
placebo response from the effectiveness side of the equation.
However, the same method is not applied to the cost side: instead
of subtracting from the cost of active treatment, the cost of
placebo is ignored. This leads to an inaccurate estimation of the
incremental cost of treatment relative to the incremental effects
and, consequently, of the incremental cost-effectiveness ratio
(ICER). We propose a method whereby both the costs and effects
of placebo are incorporated into CEA. A CEA of Sativex in
oncology pain will be used to illustrate the proposed approach.
Results will be presented. In recognition of the clinical beneﬁt
that can be effected via the placebo response, RCTs have been
designed to measure this response and to deduce the true effect of
an active therapy. CEAs, which typically use data from these
RCTs, should adopt a similar approach. Economic analyses
should not only consider the effect but also the costs of placebo
to achieve a more accurate prediction of the ICER for an active
therapy.
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OBJECTIVE: Patients in adult intensive care units (ICUs)
require multidisciplinary care that frequently result in substan-
tial morbidity, mortality, and costs. Telemedicine has been used
to provide remote intensivist monitoring for ICUs. We mea-
sured the economic and clinical outcomes associated with Tele-
ICU monitoring in 6 ICUs (5 hospitals) across the Houston
metropolitan area. METHODS: We assessed the cost and effec-
tiveness of Tele-ICU by comparing the economic and clinical
outcomes in the period after the full implementation of the
Tele-ICU (post period) with the economic and clinical outcomes
in the baseline period before the introduction of the Tele-ICU
(pre period). The cost analysis in this study adopts a hospital
perspective because the decision to implement a Tele-ICU is
made at the hospital or health system level. Costs were mea-
sured using hospital costs and the cost of operating the Tele-
ICU. Hospital costs were computed using average daily ICU
costs and ﬂoor costs for patients in each ICU during the two
study periods using individual patient data (4390 patients). ICU
and hospital length of stay (LOS) and ICU and hospital mor-
tality were obtained from chart reviews. RESULTS: Average
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